Global Indemnity Group, LLC has appointed Jessica Buss to its Board of Directors, replacing Bruce Lederman who retired. Buss brings extensive experience in specialty insurance, underwriting, and finance, having led companies like GuideOne Insurance and Open Lending. Her addition supports GBLI's growth strategy, including the rollout of its Kaleidoscope technology platform. This move aims to strengthen GBLI's position as a profitable specialty insurer with a focus on long-term growth and risk management.
Global Indemnity Group, LLC's board appointment news provides context for readers interested in financial sector trends. For readers following Financials, here is Pluang's market snapshot as of Oct 28, 2026 03:12 WIB: out of 142 priced US Financials stocks, 78 rose and 63 fell. Notable movers include HUT at USD 67.29 with a 6.86% increase and 96% buy activity, WULF at USD 12.71 with a 6.14% rise and 60% buy activity, and TCPC at USD 4.14 with a 6.01% gain and 100% buy activity, with typical hold times ranging from 12 to 91 days.
The global drone defense system market is projected to grow from $4.72 billion in 2025 to $18.19 billion by 2030, driven by increasing unauthorized drone incidents and demand for advanced detection and countermeasure technologies. Growth is fueled by...
Eli Lilly has outpaced Novo Nordisk in the GLP-1, obesity, and Type 2 Diabetes market, achieving a $1.21 trillion valuation. While Novo Nordisk's share price has fallen back after earlier gains and revenue growth remains flat, its management's strate...
argenx SE announced it will stop its Phase 3 UNITY study of efgartigimod subcutaneous for moderate-to-severe Sjögren's disease after an independent committee found the trial unlikely to meet its primary goal. This decision caused the company's stock ...
Pomerantz LLP is investigating DaVita Inc. for potential securities fraud following a sharp stock price drop triggered by a new U.S. federal strategy targeting the dialysis market. The Department of Health and Human Services announced a plan to incre...
Pomerantz LLP is investigating ClearPoint Neuro and its executives for possible securities fraud following a significant stock price drop. The decline occurred after ClearPoint's partner, uniQure, announced that their Huntington's disease treatment f...
